Proneurogen, Inc
Tucson, AZ · Biotech · Private
PNA5ER, a novel Angiotensin 1-7 derivative peptide therapeutic formulated as an extended-release subcutaneous injection
proneurogen.com →- Grants
- $5.6M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 0 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID) | $222,855 | |
| Federal grant | Department of Health and Human Services · Phase I · Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID) | $405,415 | |
| Federal grant | Department of Health and Human Services · Phase I · Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID) | $182,560 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel formulations of Allopregnanolone to treat Alzheimer's Disease | $449,886 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel formulations of Allopregnanolone to treat Alzheimer's Disease | $449,886 | |
| Federal grant | Department of Health and Human Services · Phase I · Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment | $439,355 | |
| Federal grant | Department of Health and Human Services · Phase I · Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment | $439,355 | |
| Federal grant | Department of Health and Human Services · Phase I · Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias | $499,598 | |
| Federal grant | Department of Health and Human Services · Phase I · Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias | $499,598 | |
| Federal grant | Department of Health and Human Services · Phase I · Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia | $499,763 | |
| Federal grant | Department of Health and Human Services · Phase I · Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia | $499,763 | |
| Federal grant | Department of Health and Human Services · Phase I · GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular | $499,545 | |
| Federal grant | Department of Health and Human Services · Phase I · GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: ANovel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular | $499,545 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3221 | Rondo Therapeutics | — | — |
| 3222 | GROW BIOMEDICINE LLC | — | — |
| 3223 | VELUM INC | — | — |
| 3224 | Proneurogen, Inc | — | — |
| 3225 | CLARADELE PHARMACEUTICALS, INCORPORATED | — | — |
| 3226 | Quercus Molecular Design, LLC | — | — |
| 3227 | CELLGORTHMICS, INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Extended-release Injectable Gel Formulations Containing ANGIOTENSIN-(1-7) Oligopeptides Or Variants Thereofapplication
- Extended-release Injectable Gel Formulations Containing ANGIOTENSIN-(1-7) Oligopeptides Or Variants Thereofapplication
- ANG-(1-7) Oligopeptide Derivatives For Use In Mitigating Amyloid-related Imaging Abnormalitiesapplication
- Extended-release Injectable Gel Formulations Containing ANGIOTENSIN-(1-7) Oligopeptides Or Variants Thereofapplication
- Extended-release Injectable Gel Formulations Containing ANGIOTENSIN-(1-7) Oligopeptides Or Variants Thereofapplication
- ANG-(1-7) Oligopeptide Derivatives For Use In Mitigating Amyloid-related Imaging Abnormalitiesapplication
- ANG-(1-7) Oligopeptide Derivatives For Use In Mitigating Amyloid-related Imaging Abnormalitiesapplication
- Extended-release Injectable Gel Formulations Containing ANGIOTENSIN-(1-7) Oligopeptides Or Variants Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.